Kronos Bio, Inc.
DelistedCIK 1741830fmd_04CF04AEPGC5W5KQ0BF6M2BDT8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Mar 31, 2025, 26 periods
Latest annual · FY2024
Millions- Total revenues
- 10
- Operating income
- (93)
- Net income
- (86)
- Free cash flow
- (65)
Latest quarter · Q1 FY2025
Millions- Total revenues
- 2
- Operating income
- (9)
- Net income
- (8)
- Free cash flow
- (13)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- n/m
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
Kronos Bio, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $9.8 million | $6.3 million | +56.6% | 10-K 2025-03-18 · proof |
| Operating income | -$92.9 million | -$122.1 million | 10-K 2025-03-18 · proof | |
| Net income | -$86.1 million | -$112.7 million | 10-K 2025-03-18 · proof | |
| Cash from operating activities | -$65.4 million | -$78.6 million | 10-K 2025-03-18 · proof | |
| Free cash flow | -$65.4 million | -$79.3 million | 10-K 2025-03-18 · proof | |
| Total assets | $124.4 million | $213.3 million | -41.7% | 10-K 2025-03-18 · proof |
| Total liabilities | $36.8 million | $54.2 million | -32.1% | 10-K 2025-03-18 · proof |
| Cash and cash equivalents | $84.6 million | $64.3 million | +31.5% | 10-K 2025-03-18 · proof |
- What was Kronos Bio, Inc.'s revenue in fiscal 2024?
- Kronos Bio, Inc. reported revenue of $9.8 million for fiscal 2024 (the year ended Dec 31, 2024), against $6.3 million the year before (+56.6%). Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What was Kronos Bio, Inc.'s operating income in fiscal 2024?
- Kronos Bio, Inc. reported operating income of -$92.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$122.1 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What was Kronos Bio, Inc.'s net income in fiscal 2024?
- Kronos Bio, Inc. reported net income of -$86.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$112.7 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What was Kronos Bio, Inc.'s cash from operating activities in fiscal 2024?
- Kronos Bio, Inc. reported cash from operating activities of -$65.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$78.6 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What was Kronos Bio, Inc.'s free cash flow in fiscal 2024?
- Kronos Bio, Inc. reported free cash flow of -$65.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$79.3 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What are Kronos Bio, Inc.'s total assets?
- As of Dec 31, 2024, Kronos Bio, Inc. reported total assets of $124.4 million, against $213.3 million a year earlier (-41.7%). Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What are Kronos Bio, Inc.'s total liabilities?
- As of Dec 31, 2024, Kronos Bio, Inc. reported total liabilities of $36.8 million, against $54.2 million a year earlier (-32.1%). Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
- What are Kronos Bio, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Kronos Bio, Inc. reported cash and cash equivalents of $84.6 million, against $64.3 million a year earlier (+31.5%). Source: the 10-K filed with the SEC on Mar 18, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1741830&period_type=annual&limit=5"Information only, not investment advice.